Literature DB >> 11549496

Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction.

S W Kim1, J Paick, D W Park, I Chae, B Oh.   

Abstract

OBJECTIVES: To prospectively define the potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction using a simple and practical method. Most patients with vasculogenic erectile dysfunction are known to have at least one significant cardiovascular risk factor.
METHODS: After baseline evaluations, patients with erectile dysfunction of presumed vascular origin, who were older than 45 years and with no history of ischemic heart disease, were enrolled in the study. According to the results of repeated pharmacologic erection tests, we divided patients into responders and nonresponders. The cardiologic evaluations consisted of a comprehensive history taking, the assessment of cardiovascular risk factors, a physical examination, and an exercise treadmill test.
RESULTS: A total of 97 patients completed the study. Fifteen (32.6%) of 46 responders and 25 (49.0%) of 51 nonresponders, respectively, had two or more cardiovascular risk factors (P = 0.101). Ischemic ST-segment changes on the exercise treadmill test were only observed in 8 nonresponders (15.7%) (P = 0.006). All these patients were older than 55 years, and seven had two or more cardiovascular risk factors, including hypertension.
CONCLUSIONS: On the basis of these preliminary data, we suggest that cardiovascular evaluations may prove beneficial before prescribing sildenafil to patients with vasculogenic erectile dysfunction who are nonresponders to the pharmacologic erection test, are older than 55 years, and have two or more risk factors, including hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549496     DOI: 10.1016/s0090-4295(01)01210-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil.

Authors:  O Özdabakoğlu; S Güllülü; S Sağ; T Şentürk; H Kiliçarslan; A Tütüncü; M Keçebaş; I Baran; A Aydinlar
Journal:  Int J Impot Res       Date:  2016-12-08       Impact factor: 2.896

Review 2.  [Metabolic syndrome and erectile dysfunction. Epidemiologic associations and pathogenetic links].

Authors:  A Wirth; M Manning; H Büttner
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

3.  A prospective study of the effect of antihypertensive medications on the sexual functions of hypertensive adult male patients.

Authors:  Akinwumi Akinyinka Akinyede; Obiyo Nwaiwu; Olumuyiwa John Fasipe; Adedunni Olusanya; Sunday Olufemi Olayemi; Bisola Akande
Journal:  Future Sci OA       Date:  2020-06-02

Review 4.  Erectile dysfunction: symptom or disease?

Authors:  C Foresta; N Caretta; A Aversa; C Bettocchi; G Corona; S Mariani; M Rossato
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

Review 5.  Erectile dysfunction in the cardiac patient.

Authors:  Robert A Kloner
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 3.092

6.  Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment.

Authors:  Valter Javaroni; Mario Fritsch Neves
Journal:  Int J Hypertens       Date:  2012-05-09       Impact factor: 2.420

Review 7.  Sexual function in hypertensive patients receiving treatment.

Authors:  Thorsten Reffelmann; Robert A Kloner
Journal:  Vasc Health Risk Manag       Date:  2006
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.